A user switched from finasteride to dutasteride and from topical to oral minoxidil, experiencing significant hair shedding. They plan to continue this regimen for a year before deciding on any changes.
A user shared their 14-month progress using Pyrilutamide and Minoxidil for hair loss, noting improvement and no side effects with these treatments, unlike their negative experiences with Finasteride and RU58841. They emphasized the importance of consistent application for seeing results.
A user's 8 month progress with treatments including dutasteride, minoxidil, RU58841, derma roller, ketoconazole shampoo and stemoxydine to combat hair loss. Others have shared their own experiences and regrowth results with similar treatments.
PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.
The conversation discusses combining oral dutasteride with topical finasteride to further reduce scalp DHT levels for hair regrowth. Users debate the effectiveness and safety of this combination, with some suggesting alternatives like topical antiandrogens such as RU58841, fluridil, and alfatradiol.
A user made a 70/30 ethanol/propylene glycol topical finasteride solution but noticed chunks at the bottom. The discussion focuses on this issue with the DIY hair loss treatment.
Hair loss treatments like finasteride, minoxidil, dutasteride, and RU58841. Users suggest hair fibers for temporary coverage and consider hair transplants for permanent solutions.
The user has been using finasteride for almost two years but is considering switching to dutasteride and is curious about adding RU58841. They decide to stick with dutasteride due to concerns about RU58841's safety.
RU58841 from Amazon is unreliable, with users reporting no benefits and side effects like eye swelling and chest pain. Rudirect is recommended for purchasing in Europe.